Patents by Inventor Howard Allen Ketelson

Howard Allen Ketelson has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 12268779
    Abstract: The present invention is directed to an ophthalmic emulsion. The emulsion has a unique combination of ingredients that promotes the stability of small oil droplets within the emulsion. The emulsion also includes a mucoadhesive polymer that aid in delivering a lipid to the ocular surface.
    Type: Grant
    Filed: May 18, 2023
    Date of Patent: April 8, 2025
    Assignee: Alcon Inc.
    Inventors: Howard Allen Ketelson, David L. Meadows
  • Patent number: 12247028
    Abstract: The present invention provides in one aspect azabicyclo and diazepine derivatives useful as modulators of muscarinic receptors. In another aspect, the present invention provides pharmaceutical compositions for treating ocular diseases, the compositions comprising at least one muscarinic receptor modulator.
    Type: Grant
    Filed: November 30, 2023
    Date of Patent: March 11, 2025
    Assignee: Alcon Inc.
    Inventors: David Ellis, Howard Allen Ketelson
  • Patent number: 12102559
    Abstract: Polymeric eye inserts are provided that may be dissolvable when placed in the cul-de-sac of the eye. These inserts may contain one or more polymers as well as a softener/plasticizer so that, when inserted into the eye, they may absorb tears, and dissolve and slowly release lubricant into the tear film to lubricate and protect the ocular surface for an extended duration of time. Increased retention time on the ocular surface for longer lasting relief may reduce dosing frequency and patient burden typically associated with topical drop usage. These polymeric eye inserts also may include one or more pharmaceutically active agents.
    Type: Grant
    Filed: May 1, 2020
    Date of Patent: October 1, 2024
    Assignee: Alcon Inc.
    Inventors: Howard Allen Ketelson, Rekha Rangarajan, Walter R Laredo, Stephen John Collins
  • Publication number: 20240307355
    Abstract: The present disclosure is directed to pharmaceutical compositions comprising apraclonidine and a polymer, wherein the apraclonidine is present at greater than 0.05% (w/v) to no more than 0.2% (w/v) based on the total volume of the pharmaceutical composition, methods of preparing the same and methods for reducing ocular redness by administering the same.
    Type: Application
    Filed: March 14, 2024
    Publication date: September 19, 2024
    Inventors: Rekha Rangarajan, Howard Allen Ketelson, Randall Renato Kolega, Mark Joseph Bridle, Alexei Grigoryevich Merzlikine
  • Publication number: 20240166691
    Abstract: The present disclosure is directed to prodrugs, compositions including prodrugs, and methods for administering prodrugs and compositions thereof to a patient, including prodrugs represented by Formula (I): wherein: D is a drug moiety; Q is an oxygen atom, a sulfur atom, or a nitrogen atom; X is a chemical bond or each of G, G?, and G? is independently an oxygen atom or a sulfur atom; L is a polyether; T is a hydrogen atom, a hydroxyl group, a thiol group, a boronic acid group, or an amine group; R1 is selected from the group consisting of a substituted aryl group, unsubstituted aryl group, and a substituted carbonyl group; and each of R2, R3, R1?, R2?, R3?, and R4? is independently a hydrogen atom, a substituted C1-C20 alkyl group, or an unsubstituted C1 -C20 alkyl group. In at least one embodiment, a composition comprises a compound and a carrier material.
    Type: Application
    Filed: November 7, 2023
    Publication date: May 23, 2024
    Inventors: Howard Allen Ketelson, Rekha Rangarajan
  • Publication number: 20240132497
    Abstract: The present invention provides in one aspect azabicyclo and diazepine derivatives useful as modulators of muscarinic receptors. In another aspect, the present invention provides pharmaceutical compositions for treating ocular diseases, the compositions comprising at least one muscarinic receptor modulator.
    Type: Application
    Filed: November 30, 2023
    Publication date: April 25, 2024
    Inventors: David Ellis, Howard Allen Ketelson
  • Publication number: 20240099970
    Abstract: The present disclosure is directed, in part, to aqueous pharmaceutical solutions comprising benzyl atropine or a pharmaceutically acceptable salt or prodrug thereof, at least one buffer, at least one tonicity agent, and at least one solubilizing agent, processes of preparing an aqueous solution comprising benzyl atropine, the products of such processes, and methods of preventing myopia, treating myopia, reducing myopia progression, or preventing myopia progression in a subject in need thereof, by administering to the eye of the subject a therapeutically effective amount of such an aqueous pharmaceutical solution.
    Type: Application
    Filed: September 7, 2023
    Publication date: March 28, 2024
    Inventors: Howard Allen Ketelson, Rekha Rangarajan
  • Patent number: 11884666
    Abstract: The present invention provides in one aspect azabicyclo and diazepine derivatives useful as modulators of muscarinic receptors. In another aspect, the present invention provides pharmaceutical compositions for treating ocular diseases, the compositions comprising at least one muscarinic receptor modulator.
    Type: Grant
    Filed: March 21, 2022
    Date of Patent: January 30, 2024
    Assignee: Alcon Inc.
    Inventors: David Ellis, Howard Allen Ketelson
  • Publication number: 20230372236
    Abstract: Polymeric eye inserts are provided that may be dissolvable when placed in the cul-de-sac of the eye. These inserts may contain one or more polymers as well as a softener/plasticizer so that, when inserted into the eye, they may absorb tears, and dissolve and slowly release lubricant into the tear film to lubricate and protect the ocular surface for an extended duration of time. Increased retention time on the ocular surface for longer lasting relief may reduce dosing frequency and patient burden typically associated with topical drop usage. These polymeric eye inserts also may include one or more pharmaceutically active agents.
    Type: Application
    Filed: October 5, 2021
    Publication date: November 23, 2023
    Inventors: Stephen John COLLINS, Howard Allen KETELSON, Walter R. LAREDO
  • Patent number: 11779537
    Abstract: Polymeric eye inserts are provided that may be dissolvable when placed in the cul-de-sac of the eye. These inserts may contain one or more mucoadhesive polymers, a biodegradable polymer as well as softener/plasticizer so that, when inserted into the eye, they may absorb tears, and dissolve and slowly release lubricant into the tear film to lubricate and protect the ocular surface for an extended duration of time. The biodegradable polymer containing eye insert may increase dissolution time on the ocular surface for longer lasting relief, may reduce dosing frequency and patient burden typically associated with topical drop usage. These polymeric eye inserts also may include one or more pharmaceutically active agents.
    Type: Grant
    Filed: June 23, 2022
    Date of Patent: October 10, 2023
    Assignee: Alcon Inc.
    Inventors: Howard Allen Ketelson, Rekha Rangarajan
  • Publication number: 20230285443
    Abstract: The present invention relates to artificial tear compositions and ophthalmic compositions suitable for drug delivery, In one embodiment of the present invention; the compositions comprise a galactomannan polymer such as guar or hydroxypropyl guar, hyaluronic acid, and a cis-diol such as sorbitol. In a preferred embodiment, the compositions also comprise a borate compound.
    Type: Application
    Filed: May 17, 2023
    Publication date: September 14, 2023
    Inventors: James W. Davis, Howard Allen Ketelson, Elaine E. Campbell, David L. Meadows, Rekha Rangarajan
  • Publication number: 20230285289
    Abstract: The present invention is directed to an ophthalmic emulsion. The emulsion has a unique combination of ingredients that promotes the stability of small oil droplets within the emulsion. The emulsion also includes a mucoadhesive polymer that aid in delivering a lipid to the ocular surface.
    Type: Application
    Filed: May 18, 2023
    Publication date: September 14, 2023
    Inventors: Howard Allen Ketelson, David L. Meadows
  • Patent number: 11730699
    Abstract: The present invention is directed to a lipid-based ophthalmic emulsion. The emulsion has an increased amount of a mucoadhesive galactomannan polymer that promotes a long-lasting protection against desiccation and moisture retention.
    Type: Grant
    Filed: January 12, 2021
    Date of Patent: August 22, 2023
    Assignee: Alcon Inc.
    Inventors: Howard Allen Ketelson, James W. Davis, Rekha Rangarajan
  • Patent number: 11690802
    Abstract: The present invention is directed to an ophthalmic emulsion. The emulsion has a unique combination of ingredients that promotes the stability of small oil droplets within the emulsion. The emulsion also includes a mucoadhesive polymer that aid in delivering a lipid to the ocular surface.
    Type: Grant
    Filed: March 12, 2021
    Date of Patent: July 4, 2023
    Assignee: Alcon Inc.
    Inventors: Howard Allen Ketelson, David L. Meadows
  • Publication number: 20230201030
    Abstract: A dissolvable medical device for placing on the outer exposed surface of the eye to deliver a drug to the eye comprising: a polymeric film has sufficient dimensions to substantially cover a cornea when applied to an eye, wherein the polymeric film comprising one or more mucoadhesive polymers. The polymeric film dissolves between 15 minutes to 120 minutes to release the mucoadhesive and the pharmaceutically active agents after applying the polymeric film to the eye. The dissolved polymeric film is not impeding visualization of ocular tissue while maintaining a protective film on outer surface of the eye.
    Type: Application
    Filed: December 22, 2022
    Publication date: June 29, 2023
    Inventors: Howard Allen Ketelson, Rekha Rangarajan
  • Publication number: 20230201031
    Abstract: A dissolvable medical device for placing on the outer exposed surface of the eye to heal the corneal wound comprising of: a polymeric film has sufficient dimensions to substantially cover a cornea when applied to an eye, wherein the polymeric film comprising one or more mucoadhesive polymers, wherein the polymeric film dissolves between 15 minutes to 120 minutes to release the mucoadhesive polymers, wherein the dissolved polymeric film is not impeding visualization of ocular tissue while maintaining a protective film on outer surface of the eye.
    Type: Application
    Filed: December 22, 2022
    Publication date: June 29, 2023
    Inventors: Howard Allen Ketelson, Rekha Rangarajan
  • Publication number: 20230201112
    Abstract: A dissolvable medical device for protecting a corneal surface and providing lubrication and hydration to the corneal surface during ophthalmic surgery comprising: a polymeric film has sufficient dimensions to substantially cover a cornea when applied to an eye, wherein the polymeric film comprising one or more mucoadhesive polymers. The polymeric film dissolves between 15 minutes to 120 minutes to release the mucoadhesive polymers after applying the polymeric film to the eye and the polymeric film provides more effective corneal surface protection relative to a saline treatment based on Mean Green Fluorescence Index test (demonstrates corneal damage) during a simulated surgery. In addition, a kit for use in ophthalmic surgical procedures comprises 1) the at least one dissolvable medical device and 2) at least one viscosurgical viscoelastic or at least one ophthalmoscopic surgical contact lens.
    Type: Application
    Filed: December 22, 2022
    Publication date: June 29, 2023
    Inventors: Howard Allen Ketelson, Rekha Rangarajan, Patrick John Sadd
  • Patent number: 11672820
    Abstract: The present invention relates to artificial tear compositions and ophthalmic compositions suitable for drug delivery. In one embodiment of the present invention, the compositions comprise a galactomannan polymer such as guar or hydroxypropyl guar, hyaluronic acid, and a cis-diol such as sorbitol. In a preferred embodiment, the compositions also comprise a borate compound.
    Type: Grant
    Filed: May 19, 2022
    Date of Patent: June 13, 2023
    Assignee: Alcon Inc.
    Inventors: James W. Davis, Howard Allen Ketelson, Elaine E. Campbell, David L. Meadows, Rekha Rangarajan
  • Publication number: 20220323346
    Abstract: Polymeric eye inserts are provided that may be dissolvable when placed in the cul-de-sac of the eye. These inserts may contain one or more mucoadhesive polymers polymers, a biodegradable polymer as well as softener/plasticizer so that, when inserted into the eye, they may absorb tears, and dissolve and slowly release lubricant into the tear film to lubricate and protect the ocular surface for an extended duration of time. The biodegradable polymer containing eye insert may increase dissolution time on the ocular surface for longer lasting relief, may reduce dosing frequency and patient burden typically associated with topical drop usage. These polymeric eye inserts also may include one or more pharmaceutically active agents.
    Type: Application
    Filed: June 23, 2022
    Publication date: October 13, 2022
    Inventors: Howard Allen Ketelson, Rekha Rangarajan
  • Publication number: 20220273699
    Abstract: The present invention relates to artificial tear compositions and ophthalmic compositions suitable for drug delivery. In one embodiment of the present invention, the compositions comprise a galactomannan polymer such as guar or hydroxypropyl guar, hyaluronic acid, and a cis-diol such as sorbitol. In a preferred embodiment, the compositions also comprise a borate compound.
    Type: Application
    Filed: May 19, 2022
    Publication date: September 1, 2022
    Inventors: James W. Davis, Howard Allen Ketelson, Elaine E. Campbell, David L. Meadows, Rekha Rangarajan